{"title": "Verdachtsf\u00e4lle von Impfkomplikationen nach dem Infektionsschutzgesetz und Verdachtsf\u00e4lle von Nebenwirkungen (von Impfstoffen) nach dem Arzneimittelgesetz vom 1. 1. 2004 bis zum 31. 12. 2005 - Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz", "author": "Wei\u00dfer; K; Meyer; C; Petzold; D; Mentzer; B", "url": "https://link.springer.com/article/10.1007/s00103-007-0368-6", "hostname": "springer.com", "description": "Sufficient post-marketing surveillance is necessary for safety monitoring of vaccines. In this respect the spontaneous reporting system of reporting suspected adverse drug reactions (ADR) following vaccination is an essential tool for safety monitoring. The marketing authorisation holder and/or pharmaceutical manufacturer has the legal obligation to report suspected adverse drug reactions (German Drug Law and European Regulation). In addition physicians and traditional healers have to report suspected cases of complications after immunisations pursuant to the German Infection Protection Act (Infektionsschutzgesetz, IfSG). The reports are medically assessed and stored in a database at the Paul Ehrlich Institute. For the publication referenced here, all reported suspected cases of adverse drug reactions after immunisations were evaluated for the period from January 1, 2004\u2013December 31, 2005 according to different criteria. In 2004 (2005) a total of 1237 (1393) suspected cases of adverse drug reactions or suspected complications after immunisations were notified. 858 (919) of these adverse drug reactions (ADR) were serious (69 % and 66 %, respectively). 414 (517) of the ADRs (i.e. 33 % and 37 %, respectively) were reported by physicians according to the IfSG; the other reports were from industry and other reporting sources. 251 (229) i.e. 61 % (44 %) of these reactions were serious. The total number of reports divided by the total number of vaccine doses launched on the German market during the observation period (according to the data provided by the pharmaceutical industry) revealed an overall \u201creporting rate\u201d of approx. 3 reports per 100,000 vaccine doses. The age groups with the highest absolute number of reported cases were infants and young children (0-2 years), and adults (18-59 years) accounting for approx. one third each of the reports. The age distribution of the suspected cases was comparable with that of previous years. In both years, approx. half of all suspected adverse drug reactions following immunisation were of transient nature, i.e. there was a complete recovery (restitutio ad integrum). In both years, a very small proportion of cases were reported as permanent damage (30 and 34 cases respectively; 2.4 % of all cases) or resulted in death (35 or 23 cases, respectively; 2.8 % or 1.7 %, respectively). With a few exceptions these adverse events were considered to be related to other diseases and unlikely related to vaccination. Overall, the association between vaccination and adverse events was assessed by the PEI as \u201cpossible\u201d in 58 % (62 %) of all cases, respectively, as \u201clikely\u201d in 6 % (8 %) of all cases, and as \u201ccertain\u201d in 0.4 % (0.6 %) of all cases. In 14 % (13 %) of the cases, the causal relation was stated as \u201cunlikely\u201d. In 17 % (15 %) of all cases, a scientific evaluation was not possible on the basis of the data provided. A separate analysis of reports was conducted for all suspected adverse drug reactions following varicella immunisation. According to these data varicella vaccination is considered to be well tolerated. With the exception of an increase in local reactions following pneumococcal polysaccharide vaccination no new safety signal has been recognised during the observation period.", "sitename": "SpringerLink", "date": "2007-11-07", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Zusammenfassung\nDas Spontanerfassungssystem zu Verdachtsf\u00e4llen von Nebenwirkungen (Synonym: unerw\u00fcnschte Arzneimittelwirkungen, UAW), als eine Methode der passiven Surveillance, stellt das wichtigste Instrument zum m\u00f6glichst zeitnahen Erkennen von neuen seltenen Risikosignalen dar. F\u00fcr Impfstoffe besteht in Deutschland neben der Meldeverpflichtung des Zulassungsinhabers und/oder pharmazeutischen Unternehmers nach dem Arzneimittelgesetz (AMG) und der standesrechtlichen Verpflichtung zur Meldung von Nebenwirkungen eine gesetzliche Meldeverpflichtung von \u00c4rzten und Heilpraktikern zu Verdachtsf\u00e4llen von Impfkomplikationen nach dem Infektionsschutzgesetz (IfSG). Die Meldungen werden im Paul-Ehrlich-Institut unabh\u00e4ngig vom Kausalzusammenhang zentral in einer Datenbank erfasst und wissenschaftlich bewertet. F\u00fcr die vorliegende Publikation wurden alle gemeldeten Verdachtsf\u00e4lle von Nebenwirkungen und Impfkomplikationen aus dem Zeitraum 1.1.2004 bis 31.12.2005 ausgewertet. In den Jahren 2004 (2005) wurden 1237 (1393) Verdachtsf\u00e4lle \u00fcber Impfnebenwirkungen bzw. Impfkomplikationen gemeldet, davon 858 (919) schwerwiegende [69 % (66 %)]. Bei 414 (517) bzw. 33 % (37 %) der Meldungen handelte es sich um einen Bericht \u00fcber Verdachtsf\u00e4lle einer \u00fcber das \u00fcbliche Ausma\u00df einer Impfreaktion hinausgehenden gesundheitlichen Sch\u00e4digung (Verdacht auf Impfkomplikation) nach Infektionsschutzgesetz (IfSG). Davon waren 251 (229) bzw. 61 % (44 %) schwerwiegend. Wenn man die Gesamtzahl aller Verdachtsf\u00e4lle mit der Gesamtzahl der in Deutschland verkauften Impfstoffdosen nach Angaben der pharmazeutischen Unternehmer in Beziehung setzt, ergibt sich f\u00fcr beide Jahre eine auf alle Impfstoffe bezogene Melderate von ca. 3 Verdachtsf\u00e4llen pro 100.000 Impfstoffdosen. Die beiden Altersgruppen mit der h\u00f6chsten absoluten Zahl von Verdachtsf\u00e4llen sind die S\u00e4uglinge und Kleinkinder (0\u2013 2 Jahre) und die Erwachsenen (18\u201359 Jahre) mit je ca. einem Drittel der Verdachtsf\u00e4lle. Die Altersverteilung der Verdachtsf\u00e4lle war vergleichbar mit der in den Vorjahren. Etwa die H\u00e4lfte aller gemeldeten Impfreaktionen waren vor\u00fcbergehender Natur, f\u00fchrten also zur v\u00f6lligen Wiederherstellung (Restitutio ad integrum). Sowohl im Jahr 2004 als auch im Jahr 2005 wurden wenige F\u00e4lle mit bleibendem Schaden [30 (34) F\u00e4lle; jew. 2,4 % aller F\u00e4lle] oder Tod [35 (23) F\u00e4lle; 2,8 % (1,7 %)] gemeldet. Bei der Mehrzahl dieser F\u00e4lle wurde der Zusammenhang zwischen Impfung und unerw\u00fcnschtem(n) Ereignis(sen) als \u201eunwahrscheinlich\u201c bewertet. Insgesamt wurde der urs\u00e4chliche Zusammenhang zwischen Impfung und unerw\u00fcnschten Ereignissen vom PEI bei 58 % (62 %) aller Ereignisse als \u201em\u00f6glich\u201c, bei 6 % (8 %) als \u201ewahrscheinlich\u201c und bei 0,4 % (0,6 %) als \u201egesichert\u201c eingesch\u00e4tzt. Bei 14 % (13 %) aller Ereignisse wurde ein Zusammenhang als \u201eunwahrscheinlich\u201c angesehen. Bei ca. 17 % (15 %) aller Ereignisse war auf Basis der vorliegenden Daten eine wissenschaftliche Bewertung nicht m\u00f6glich. Da die Varizellenimpfung im Jahr 2004 in die Empfehlungen der STIKO (St\u00e4ndige Impfkommission am Robert Koch-Institut) aufgenommen wurde, wurden alle Verdachtsf\u00e4lle im Zusammenhang mit einer Varizellenimpfung aus dem Jahr 2005 einer speziellen Betrachtung unterzogen. Diese Auswertung zeigt, dass die Varizellenimpfung sehr gut vertr\u00e4glich ist. Nach einer kritischen Bewertung der wissenschaftlichen Daten zu allen Verdachtsf\u00e4llen von Impfnebenwirkungen bzw. Impfkomplikationen, die dem Paul-Ehrlich-Institut (PEI) 2004 und 2005 spontan gemeldet wurden, wurden als einziges neues Signal vermehrte Lokalreaktionen nach der Pneumokokken-Polysaccharid-Impfung identifiziert. Die Auswertung der Meldungen aus den Jahren 2004 und 2005 weist nicht auf eine \u00c4nderung des Risiko-Nutzen-Verh\u00e4ltnisses der heute in Deutschland auf dem Markt befindlichen Impfungen hin.\nAbstract\nSufficient post-marketing surveillance is necessary for safety monitoring of vaccines. In this respect the spontaneous reporting system of reporting suspected adverse drug reactions (ADR) following vaccination is an essential tool for safety monitoring. The marketing authorisation holder and/or pharmaceutical manufacturer has the legal obligation to report suspected adverse drug reactions (German Drug Law and European Regulation). In addition physicians and traditional healers have to report suspected cases of complications after immunisations pursuant to the German Infection Protection Act (Infektionsschutzgesetz, IfSG). The reports are medically assessed and stored in a database at the Paul Ehrlich Institute. For the publication referenced here, all reported suspected cases of adverse drug reactions after immunisations were evaluated for the period from January 1, 2004\u2013December 31, 2005 according to different criteria. In 2004 (2005) a total of 1237 (1393) suspected cases of adverse drug reactions or suspected complications after immunisations were notified. 858 (919) of these adverse drug reactions (ADR) were serious (69 % and 66 %, respectively). 414 (517) of the ADRs (i.e. 33 % and 37 %, respectively) were reported by physicians according to the IfSG; the other reports were from industry and other reporting sources. 251 (229) i.e. 61 % (44 %) of these reactions were serious. The total number of reports divided by the total number of vaccine doses launched on the German market during the observation period (according to the data provided by the pharmaceutical industry) revealed an overall \u201creporting rate\u201d of approx. 3 reports per 100,000 vaccine doses. The age groups with the highest absolute number of reported cases were infants and young children (0-2 years), and adults (18-59 years) accounting for approx. one third each of the reports. The age distribution of the suspected cases was comparable with that of previous years. In both years, approx. half of all suspected adverse drug reactions following immunisation were of transient nature, i.e. there was a complete recovery (restitutio ad integrum). In both years, a very small proportion of cases were reported as permanent damage (30 and 34 cases respectively; 2.4 % of all cases) or resulted in death (35 or 23 cases, respectively; 2.8 % or 1.7 %, respectively). With a few exceptions these adverse events were considered to be related to other diseases and unlikely related to vaccination. Overall, the association between vaccination and adverse events was assessed by the PEI as \u201cpossible\u201d in 58 % (62 %) of all cases, respectively, as \u201clikely\u201d in 6 % (8 %) of all cases, and as \u201ccertain\u201d in 0.4 % (0.6 %) of all cases. In 14 % (13 %) of the cases, the causal relation was stated as \u201cunlikely\u201d. In 17 % (15 %) of all cases, a scientific evaluation was not possible on the basis of the data provided. A separate analysis of reports was conducted for all suspected adverse drug reactions following varicella immunisation. According to these data varicella vaccination is considered to be well tolerated. With the exception of an increase in local reactions following pneumococcal polysaccharide vaccination no new safety signal has been recognised during the observation period.\nThis is a preview of subscription content,\n[access via\nyour institution](//wayf.springernature.com?redirect_uri=https%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs00103-007-0368-6%3Ferror%3Dcookies_not_supported%26code%3De0c26e6f-687b-4c1b-b36e-a376440c7e55).\nAccess options\nBuy single article\nInstant access to the full article PDF.\n39,95 \u20ac\nPrice includes VAT (Germany)\nLiteratur\nKeller-Stanislawski B, et al. (2004) Verdachtsf\u00e4lle von Impfkomplikationen nach dem Infektionsschutzgesetz und Verdachtsf\u00e4lle von Nebenwirkungen nach dem Arzneimittelgesetz vom 1. 1. 2001 bis zum 31. 12. 2003. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 47:1151\u20131164. Ver\u00f6ffentlicht im Internet, URL: http://www.pei.de/DE/infos/patienten/publikat-pat/functions/impf-node.html\nDefinitionen zu Nebenwirkungen \u2013 Pharmakovigilanz, ver\u00f6ffentlicht im Internet, URL: http://www.pei.de/DE/infos/fachkreise/pharmakovigilanz/nw-pharm/nw-pharm-node.html\nBekanntmachung zur Anzeige von Nebenwirkungen und Arzneimittelmissbrauch nach \u00a7 63 b Abs. 1 bis 8 des Arzneimittelgesetzes (AMG). Bundesanzeiger Nr. 97 vom 28. Mai 2005, S. 8029\nInstitute of Medicine: Immunization Safety Review (2003) Vaccines and Sudden Unexpected Death in Infancy. The National Academies Press\nNaleway, et al. (2006) Delivering influenza vaccine to pregnant women. Epidemiol Rev 28:47\u201353\nSmith NM, et al. (2006) Prevention and Control of Influenza \u2013 recommendations of the Advisory Committee on Immunization Practices (ACIP), ver\u00f6ffentlicht im Internet, URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5510a1.htm\nInstitute of Medicine (1994) Adverse events associated with childhood vaccines \u2013 Evidence bearing on causality. In: Stratton KR, Howe CJ, Johnston Jr. RB (eds). The National Academies Press\nQuast U (1999) Impfkomplikationen. Hippokrates, Stuttgart\nHarjulehto T, et al. (1989) Congenital malformations and oral poliovirus vaccination during pregnancy. Lancet 1:771\u2013772\nMultiple Sklerose und Impfungen \u2013 Hepatitis-B-Impfung, ver\u00f6ffentlicht im Internet, URL: http://www.pei.de/DE/infos/fachkreise/am-infosablage/sik/2004-10-27-ms-hbv-studien.html\nHernan MA, et al. (2006) Tetanus vaccination and risk of multiple sclerosis. Neurology 67:212\u2013215\nRutschmann, et al. (2002) Immunization and MS. A summary of published evidence and recommendations. Neurology 59:1837\u20131843\nInstitute of Medicine: Immunization Safety Review (2004) Vaccines and Autism. The National Academies Press\nWeisser K, et al. (2004) Thiomersal und Impfungen. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 47:1165\u20131174., ver\u00f6ffentlicht im Internet, URL: http://www.pei.de/DE/infos/patienten/publikat-pat/functions/impf-node.html\nKarvonen M, et al. (1999) Association between type 1 diabetes and Haemophilus influenzae type b vaccination: birth cohort study. BMJ 318:1169\u20131172\nKeller-Stanislawski B, Hartmann K (2001) Existiert ein Zusammenhang zwischen Impfungen und Typ-1-Diabetes-mellitus bei Kindern und Jugendlichen? Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 44:613\u2013618, ver\u00f6ffentlicht im Internet, URL: http://www.pei.de/DE/infos/patienten/publikat-pat/functions/impf-node.html\nHasford J, et al. (2002) Physicians' knowledge and attitudes regarding the spontaneous reporting system for adverse drug reactions. J Clin Epidemiol 55:945\u2013950\nEMEA Statement zu Hexavac, ver\u00f6ffentlicht im Internet, URL: http://www.emea.europa.eu/pdfs/human/press/p45/588903en.pdf\nKeller-Stanislawski B, L\u00f6wer J (2003) Todesf\u00e4lle in zeitlichem Zusammenhang mit Sechsfach-Impfung. Kinder Jugendarzt 34:608\u2013613\nvon Kries R, Toschke AM, Stra\u00dfburger, K, et al (2005) Sudden and unexpected deaths after the administration of hexavalent vaccines (diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, Haemophilius influenzae type b): is there a signal? Eur J Ped 164(2):61\u201369\nZinka B, Penning R (2006) Unexplained cases of sudden infant death shortly after hexavalent vaccination. Vaccine 24:5785\u20135786\nArchiv Sicherheitsinformationen zu Arzneimitteln, ver\u00f6ffentlicht im Internet, URL: http://www.pei.de/DE/infos/fachkreise/archiv-sik/archivsik-node.html_nnn=true\nSchmitt HJ (2005) A \u201csignal\u201d requires urgent action. Eur J Pediatr 164:59\u201360\nVennemann MMT, et al. (2007) Sudden infant death syndrome: no increased risk after immunisation. Vaccine 25:336\u2013340\nPressemitteilung: European Medicines Agency recommends suspension of Hexavac., ver\u00f6ffentlicht im Internet, URL:http://www.emea.eu.int/pdfs/human/press/pr/29736905en.pdf\nLasky T, et al. (1998) The Guillain-Barr\u00e9 Syndrome and the 1992\u20131993 and 1993\u20131994 influenza vaccines. NEJM 339:1797\u20131801\nFeder HM, Hoss DM (2004) Herpes Zoster in otherwise healthy children. Pediatr Infect Dis J 23:451\u2013460\nUebe B, et al. (2002) Herpes Zoster by reactivated vaccine varicella zoster virus in a healthy child. Eur J Pediatr 161:442\u2013444\nBrisson, et al. (2000) Modelling the impact of immunization on the epidemiology of varizella zoster virus. Epidemiol Infect 125:651\u2013669\nJumaan, et al. (2005) Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992\u20132002. J Infect Dis. 191(12):2002\u20132007\nMasern- und Varizellen-Sentinel, ver\u00f6ffentlicht im Internet, URL: http://www.rki.de/DE/Content/Infekt/Sentinel/Masern/masern_inhalt.html\nRobert Koch-Institut (2002) Zu den aktuellen Masern-Ausbr\u00fcchen in Deutschland. Epidemiol Bull 12\nRobert Koch-Institut (2005) Erkrankungen an Masern im Jahr 2004 und Ausbr\u00fcche in Hessen und Bayern in der ersten H\u00e4lfte des Jahres 2005. Epidemiol Bull 29\nRights and permissions\nAbout this article\nCite this article\nWei\u00dfer, K., Meyer, C., Petzold, D. et al. Verdachtsf\u00e4lle von Impfkomplikationen nach dem Infektionsschutzgesetz und Verdachtsf\u00e4lle von Nebenwirkungen (von Impfstoffen) nach dem Arzneimittelgesetz vom 1. 1. 2004 bis zum 31. 12. 2005. Bundesgesundheitsbl. 50, 1404\u20131417 (2007). https://doi.org/10.1007/s00103-007-0368-6\nPublished:\nIssue Date:\nDOI: https://doi.org/10.1007/s00103-007-0368-6", "language": null, "image": "https://media.springernature.com/w200/springer-static/cover/journal/103.jpg", "pagetype": "article", "links": ["#main-content", "https://link.springer.com", "https://link.springer.com/signup-login?previousUrl=https%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs00103-007-0368-6%3Ferror%3Dcookies_not_supported%26code%3De0c26e6f-687b-4c1b-b36e-a376440c7e55", "#header-nav", "https://link.springer.com/journals/a/1", "https://www.springernature.com/gp/authors", "#popup-search", "https://order.springer.com/public/cart", "/", "/journal/103", "#article-info", "#auth-K_-Wei_er-Aff1-Aff3", "#Aff1", "#Aff3", "#auth-C_-Meyer-Aff2", "#Aff2", "#auth-D_-Petzold-Aff1", "#Aff1", "#auth-D_-Mentzer-Aff1", "#Aff1", "#auth-B_-Keller_Stanislawski-Aff1", "#Aff1", "/journal/103", "#citeas", "/article/10.1007/s00103-007-0368-6/metrics", "//wayf.springernature.com?redirect_uri=https%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs00103-007-0368-6%3Ferror%3Dcookies_not_supported%26code%3De0c26e6f-687b-4c1b-b36e-a376440c7e55", null, "https://www.springernature.com/gp/librarians/licensing/agc/journals", "https://doi.org/10.1007%2Fs00103-004-0946-9", "/articles/cas-redirect/1:STN:280:DC%2BD2M%2FgvFynsA%3D%3D", "http://scholar.google.com/scholar_lookup?&title=&journal=Bundesgesundheitsbl%20Gesundheitsforsch%20Gesundheitsschutz&doi=10.1007%2Fs00103-004-0946-9&volume=47&publication_year=2004&author=Keller-Stanislawski%2C", "https://doi.org/10.1093%2Fepirev%2Fmxj002", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16731574", "http://scholar.google.com/scholar_lookup?&title=&journal=Epidemiol%20Rev&doi=10.1093%2Fepirev%2Fmxj002&volume=28&publication_year=2006&author=Naleway%2C", "https://doi.org/10.1016%2FS0140-6736%2889%2992584-1", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=2564574", "/articles/cas-redirect/1:STN:280:BiaC1c%2FkvV0%3D", "http://scholar.google.com/scholar_lookup?&title=&journal=Lancet&doi=10.1016%2FS0140-6736%2889%2992584-1&volume=1&publication_year=1989&author=Harjulehto%2C", "https://doi.org/10.1212%2F01.wnl.0000225079.51201.f9", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16864810", "http://scholar.google.com/scholar_lookup?&title=&journal=Neurology&doi=10.1212%2F01.wnl.0000225079.51201.f9&volume=67&publication_year=2006&author=Hernan%2C", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12499473", "http://scholar.google.com/scholar_lookup?&title=&journal=Neurology&volume=59&publication_year=2002&author=Rutschmann%2C", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10221937", "/articles/cas-redirect/1:STN:280:DyaK1M3jvVKntw%3D%3D", "http://scholar.google.com/scholar_lookup?&title=&journal=BMJ&volume=318&publication_year=1999&author=Karvonen%2C", "https://doi.org/10.1016%2FS0895-4356%2802%2900450-X", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12393084", "/articles/cas-redirect/1:STN:280:DC%2BD38njsFejtw%3D%3D", "http://scholar.google.com/scholar_lookup?&title=&journal=J%20Clin%20Epidemiol&doi=10.1016%2FS0895-4356%2802%2900450-X&volume=55&publication_year=2002&author=Hasford%2C", "http://scholar.google.com/scholar_lookup?&title=&journal=Kinder%20Jugendarzt&volume=34&publication_year=2003&author=Keller-Stanislawski%2C", "https://doi.org/10.1007%2Fs00431-004-1594-7", "http://scholar.google.com/scholar_lookup?&title=&journal=Eur%20J%20Ped&doi=10.1007%2Fs00431-004-1594-7&volume=164&publication_year=2005&author=von%20Kries%2C", "https://doi.org/10.1016%2Fj.vaccine.2006.04.003", "/articles/cas-redirect/1:CAS:528:DC%2BD28Xms1Grsrc%3D", "http://scholar.google.com/scholar_lookup?&title=&journal=Vaccine&doi=10.1016%2Fj.vaccine.2006.04.003&volume=24&publication_year=2006&author=Zinka%2C", "https://doi.org/10.1007%2Fs00431-004-1593-8", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15602673", "http://scholar.google.com/scholar_lookup?&title=&journal=Eur%20J%20Pediatr&doi=10.1007%2Fs00431-004-1593-8&volume=164&publication_year=2005&author=Schmitt%2C", "https://doi.org/10.1016%2Fj.vaccine.2006.07.027", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16945457", "/articles/cas-redirect/1:CAS:528:DC%2BD28Xht12ru7nK", "http://scholar.google.com/scholar_lookup?&title=&journal=Vaccine&doi=10.1016%2Fj.vaccine.2006.07.027&volume=25&publication_year=2007&author=Vennemann%2C", "https://doi.org/10.1056%2FNEJM199812173392501", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=9854114", "/articles/cas-redirect/1:STN:280:DyaK1M%2FmtFShsA%3D%3D", "http://scholar.google.com/scholar_lookup?&title=&journal=NEJM&doi=10.1056%2FNEJM199812173392501&volume=339&publication_year=1998&author=Lasky%2C", "https://doi.org/10.1097%2F01.inf.0000126901.88982.32", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15131470", "http://scholar.google.com/scholar_lookup?&title=&journal=Pediatr%20Infect%20Dis%20J&doi=10.1097%2F01.inf.0000126901.88982.32&volume=23&publication_year=2004&author=Feder%2C", "https://doi.org/10.1007%2Fs00431-002-0981-1", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12172829", "http://scholar.google.com/scholar_lookup?&title=&journal=Eur%20J%20Pediatr&doi=10.1007%2Fs00431-002-0981-1&volume=161&publication_year=2002&author=Uebe%2C", "https://doi.org/10.1017%2FS0950268800004714", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11218215", "/articles/cas-redirect/1:STN:280:DC%2BD3M7jsFyrug%3D%3D", "http://scholar.google.com/scholar_lookup?&title=&journal=Epidemiol%20Infect&doi=10.1017%2FS0950268800004714&volume=125&publication_year=2000&author=Brisson%2C", "https://doi.org/10.1086%2F430325", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15897984", "http://scholar.google.com/scholar_lookup?&title=&journal=J%20Infect%20Dis.&doi=10.1086%2F430325&volume=191&publication_year=2005&author=Jumaan%2C", "https://citation-needed.springer.com/v2/references/10.1007/s00103-007-0368-6?format=refman&flavour=references", "/search?dc.creator=K.%20Wei%C3%9Fer", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=K.%20Wei%C3%9Fer", "http://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22K.%20Wei%C3%9Fer%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en", "/search?dc.creator=C.%20Meyer", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=C.%20Meyer", "http://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22C.%20Meyer%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en", "/search?dc.creator=D.%20Petzold", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=D.%20Petzold", "http://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22D.%20Petzold%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en", "/search?dc.creator=D.%20Mentzer", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=D.%20Mentzer", "http://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22D.%20Mentzer%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en", "/search?dc.creator=B.%20Keller-Stanislawski", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=B.%20Keller-Stanislawski", "http://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22B.%20Keller-Stanislawski%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en", "mailto:weika@pei.de", "https://s100.copyright.com/AppDispatchServlet?title=Verdachtsf%C3%A4lle%20von%20Impfkomplikationen%20nach%20dem%20Infektionsschutzgesetz%20und%20Verdachtsf%C3%A4lle%20von%20Nebenwirkungen%20%28von%20Impfstoffen%29%20nach%20dem%20Arzneimittelgesetz%20vom%201.%201.%202004%20bis%20zum%2031.%2012.%202005&author=Dr.%20K.%20Wei%C3%9Fer%20et%20al&contentID=10.1007%2Fs00103-007-0368-6&copyright=Springer%20Medizin%20Verlag&publication=1436-9990&publicationDate=2007-11-07&publisherName=SpringerNature&orderBeanReset=true", "https://citation-needed.springer.com/v2/references/10.1007/s00103-007-0368-6?format=refman&flavour=citation", "/search?query=Impfkomplikation&facet-discipline=%20Medicine%20%26%20Public%20Health%20", "/search?query=Nebenwirkung&facet-discipline=%20Medicine%20%26%20Public%20Health%20", "/search?query=Infektionsschutzgesetz&facet-discipline=%20Medicine%20%26%20Public%20Health%20", "/search?query=Impfung&facet-discipline=%20Medicine%20%26%20Public%20Health%20", "/search?query=adverse%20drug%20reactions&facet-discipline=%20Medicine%20%26%20Public%20Health%20", "/search?query=adverse%20events%20following%20immunisation&facet-discipline=%20Medicine%20%26%20Public%20Health%20", "/search?query=German%20Infection%20Protection%20Act&facet-discipline=%20Medicine%20%26%20Public%20Health%20", "/search?query=vaccination&facet-discipline=%20Medicine%20%26%20Public%20Health%20", "//wayf.springernature.com?redirect_uri=https%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs00103-007-0368-6%3Ferror%3Dcookies_not_supported%26code%3De0c26e6f-687b-4c1b-b36e-a376440c7e55", null, "https://www.springernature.com/gp/librarians/licensing/agc/journals", "https://link.springer.com/journals/a/1", "https://www.springernature.com/gp/authors", "https://link.springer.com/journals/a/1", "https://link.springer.com/books/a/1", "https://www.springernature.com/gp/authors", "https://www.springernature.com/gp/open-research/about/the-fundamentals-of-open-access-and-open-research", "https://www.springernature.com/gp/products", "https://www.springernature.com/gp/librarians", "https://www.springernature.com/gp/societies", "https://www.springernature.com/gp/partners", "https://www.springer.com/", "https://www.nature.com/", "https://www.biomedcentral.com/", "https://www.palgrave.com/", "https://www.apress.com/", "https://www.springernature.com/gp/legal/ccpa", "https://www.springernature.com/gp/info/accessibility", "https://link.springer.com/termsandconditions", "https://link.springer.com/privacystatement", "https://support.springernature.com/en/support/home", "https://www.springernature.com/"]}